Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q3 2017 call → NOWe need answer YES/NO based on transcript. Need determine if management describes currently in middle of copying a part of its own business that already works into additional places where same demand already visible. Need identify specific proven instance, copies being stood up now, demand already identified at destination, large relative to company, results reflect original instance. Let's parse transcript. Management discusses various things. Key topics: new products (Nurse Residency Pathway, OB Risk, Knowledge Q), resuscitation products with Laerdal expiring, new strategic partners signed for resuscitation solutions to launch Jan 2019. Also patient experience moving from phone to online surveys, Provider Solutions moving from installed software to SaaS. Also mention "we’ve signed two new strategic partners in the last 100 days" for resuscitation solutions. They are preparing to bring new resuscitation solutions to market in Jan 2019. Is that copying a proven part? The existing HeartCode/RQI products are proven, but they are losing rights. They are signing new partners to bring competing products. But those new products are not yet launched, not proven. They are not "copies" of existing business being stood up now? They are new partnerships, but not yet selling. Demand? They mention customers want competency not card, but not specific demand waiting. Also they mention "we’ve signed two new strategic partners" - that is standing up? But not yet launched. Also they mention "we’re still in active business development mode to bring new partners" - not yet. Another possible: Patient Experience: they moved phone operations to Nashville, shifted from phone to online surveys. That is not copying a proven unit into new locations; it's a modality shift. Another: Provider Solutions: moving from installed software to SaaS. Not copying. Another: "we’ve recently begun to market and sale some of those products. In fact, all six products have shown revenue and some sales orders in this quarter" - new products like Nurse Residency Pathway, OB Risk. Are they copying? They are new products, not proven? They have revenue and sales orders, but are they being replicated into additional places? Not described as standing up copies. They are selling to customers, but that's normal growth.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.